LY3325656

LY3325656 is a selective GPR142 agonist. LY3325656 selectively activates GPR142. LY increases glucose-dependent insulin secretion. LY3325656 shows anti-diabetic effects. LY3325656 can be used in the research of type 2 diabetes[1][2].

Product Specifications

CAS Number

[1998714-25-2]

UNSPSC

12352005

Target

Mas-related G-protein-coupled Receptor (MRGPR)

Related Pathways

GPCR/G Protein

Field of Research

Metabolic Disease

Smiles

CC1=C(N(C)C=N1)C=2NC(=NN2)[C@@H]3C[C@H](N(C(=O)C4=CC(C(F)(F)F)=CC=C4)C)CCO3

Molecular Formula

C21H23F3N6O2

Molecular Weight

448.45

References & Citations

[1]Liu LZ, et al. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human. Bioorg Med Chem Lett. 2020 Mar 1;30 (5) :126857.|[2]Pratt E J, et al. 20-OR: GPR142 agonists increase glucose-dependent insulin secretion and differentially regulate hormone secretion in preclinical and phase 1 studies[J]. Diabetes, 2019, 68 (Supplement_1) .